Familial hypercholesterolemia (FH) is an autosomal dominant inherited genetic disorder with a prevalence historically estimated to be on the order of 1:500, but recent data suggest that it could be between 1:200 and 1:250 (1) (2) (3) . Patients with FH have elevated levels of total cholesterol and low-density lipoprotein (LDL) particles, as well as increased LDL-cholesterol (LDL-C) arterial deposits, leading to coronary heart disease (CHD) (4, 5) .
Patients with FH have cardiovascular complications at an early age and a reduced life expectancy (6) (7) . Early diagnosis followed by an aggressive cholesterol-lowering treatment regimen could prevent occurrence of cardiovascular events by reducing the long-term exposure of these patients and their affected relatives to high levels of LDL-C.
Diagnosis of FH was traditionally based on clinical algorithms and several groups have developed clinical diagnostic criteria for FH identification. Among the most widely used FH clinical criteria are those of the Simon Broome Register Group in the United
Kingdom (8) and the Dutch Lipid Clinic Network (9) .
Advances in genetic testing have made FH genetic testing affordable, but recent studies have shown that FH diagnosis by genetic testing in severely hypercholesterolemic individuals from the overall population is low (between 0.3% and 1.7%) (10, 11) . This low prevalence suggests a need to identify additional high-risk groups of patients for FH genetic testing. As such, patients with an acute coronary syndrome (ACS) could represent an optimal group for whom FH screening programs could be developed.
While the prevalence of genetically confirmed FH in patients with ACS has not been studied in detail, recent European data showed a prevalence between 1.6% and 8.3% in this group of patients when employing clinical algorithms (12) (13) (14) .
Patients with ACS and FH are at particularly elevated risk for recurrent cardiovascular complications (12) and current management of these patients focuses on aggressive lipidlowering strategies.
Prompt identification of FH among patients with ACS could be extremely useful to allow early intensification of lipid-lowering treatment and could lead to early identification of relatives with FH who have not yet experienced cardiovascular events but who would benefit from early initiation of intensive lipid-lowering therapies (9, 15, 16) .
We sought to determine the prevalence of genetically confirmed FH in patients with ACS and to evaluate the diagnostic performance of FH clinical criteria compared with FH genetic findings.
METHODS
Clinical records were reviewed for all patients age 65 years or younger hospitalized at Hospital Universitario Puerta de Hierro (Madrid, Spain) for ACS from January 1, 2012, to March 31, 2016 . All patients with real or estimated LDL-C levels 160 mg/dl (4.14 mmol/l) on admission were contacted and offered FH genetic testing. In all patients receiving statin therapy or ezetimibe before admission, LDL-C levels were estimated by multiplying their LDL-C level on treatment with correction factors considering the drug and its dose, as previously reported (17) (18) (19) . The effect of other lipid-lowering drugs was not considered.
Levels of LDL-C were calculated according to the Friedewald formula (20) . Patients were excluded from the study if triglycerides were >350 mg/dl (4 mmol/l). Patients without information on cholesterol levels at admission and those with lipid disorders secondary to renal, thyroid, or liver diseases also were excluded.
Whole blood or saliva samples for deoxyribonucleic acid (DNA) analysis were collected from patients who were accepted into the study and, simultaneously, data about their personal and family history were collected and physical examination was performed.
The patient selection process is represented in the flow chart in Figure 1 . The study protocol complied with the Declaration of Helsinki and was approved by the ethics committee of Hospital Universitario Puerta de Hierro. All participants gave written informed consent to participate in the study.
FH CLINICAL CRITERIA.
The clinical diagnosis of FH was based on 2 widely used FH clinical criteria recommended by international guidelines. The Simon Broome (SB) criteria (8) , recommended by the United Kingdom's National Institute for Health and Care
Excellence guidelines, considers a diagnosis of possible FH as a total cholesterol >290 mg/dl or LDL-C >190 mg/dl, plus a family history of premature coronary artery disease. A definite FH diagnosis requires the aforementioned cholesterol levels and the presence of tendon xanthomas in the patient or relatives (physical signs of hypercholesterolemia). The Dutch Lipid Clinic (DLC) criteria (9), endorsed by the European Society of Cardiology, the National Lipid Association in the United States, the International FH Foundation, and the European Atherosclerosis Society, considers LDL-C levels, physical signs, and a personal or family history of premature CHD (Online Tables 1 and 2 ). Possible FH is defined by a DLC criteria score of 3 to 5 and probable-definite FH by a score of ≥6. Both sets of criteria include genetic findings among the parameters to consider (which, would per se, at least for DLC clinical criteria, generate a definite diagnosis of FH). As genetic information is usually not available for most clinicians and as we wanted to compare the diagnostic performance of genetic testing with the clinical criteria, genetic information was not considered when calculating FH clinical criteria by both algorithms. DNA SEQUENCING. Genomic DNA was extracted from saliva or peripheral blood samples. Targeted enrichment was performed with a custom resequencing solution (Lipid inCode, Ferrer in Code, Barcelona, Spain). The design was based on the human reference genome (hg19) and 120 bp-length ribonucleic acid biotinylated baits were defined to extensively cover all regions of interest.
The experimental procedure was performed according to the manufacturer's instructions with some modifications as a result of our internal validations. Very briefly, 50 ng of high-quality double-stranded DNA from every sample was enzymatically fragmented and, after hybridization to the solution and capture, libraries were amplified by polymerase chain reaction and indexed. Final libraries were quantified and their quality assessed on a bioanalyzer using high-sensitivity DNA chips. All libraries were then pooled and sequenced (up to 40 per run). The sequencing paired-end process was developed on an integrated sequencing system using 2 × 75 bp reads length. The diagnostic platform used also interrogated a weighted LDL-C-raising gene score identified by the Global Lipid Genetics Consortium (Online Table 3 ), based on 12 LDL-Craising genetic variants, which determines the likelihood that a patient has polygenic hypercholesterolemia (21) . The calculation of the risk score was computed as described in Talmud et al. (21) and determined in patients without variants in FH-related genes. A gene score ≥1.08, which is the ninth decile cut-off for the Whitehall II control cohort (21) , has been proposed as highly suggestive of polygenic hypercholesterolemia (22) . 
RESULTS
The study cohort comprised 103 patients (mean age: 54 ± 6.7 years; range 37 to 65), 87.4% of whom were male, admitted for an ACS. Forty-seven were admitted for ST-elevation myocardial infarction, 47 for non-ST-elevation myocardial infarction, and 9 for unstable angina. Mean LDL-C at admission was 189.5 ± 34.7 mg/dl, but only 39 patients (37.9%) were using statin therapy. Sixteen patients (15.5%) had previous history of CHD, 3 (2.9%) had a history of stroke, and 6 (5.8%) showed peripheral artery disease. None of the patients had been diagnosed with FH previously by their primary care doctors or treating physicians.
Other clinical characteristics are presented in Table 1 .
After clinical evaluation with the DLC algorithm, 12 patients (11.7%) fulfilled criteria for definite FH and 16 patients (15.5%) had probable FH. Thus, DLC criteria classified 28 patients (27.2%) with probable or definite FH. Based on SB criteria, 28 patients (27.1%) had definite (2 patients; 1.9%) or possible (26; 25.2%) FH ( Table 2) .
Genetic testing revealed 9 heterozygous pathogenic or likely pathogenic FH mutations in 9 individuals (8.7%). Seven mutations were found in the LDLR gene, 1 in PCSK9, and 1 in STAP1 (Online Table 4 ). Five VUS were also found in patients with pathogenic or likely pathogenic FH mutations. Thirty-two patients carried 35 VUS and 62 individuals (60.2%) had no genetic variation in FH-related genes. Additionally, 7 patients were heterozygous for variants in LDLRAP1 (autosomal recessive hypercholesterolemia) and 5 patients carried heterozygous variants in the LIPA gene (homozygous mutations in this gene cause lysosomal acid lipase deficiency) (Online Table 4 ).
Familial genetic evaluation was offered to first-degree relatives of the 9 patients with pathogenic or likely pathogenic mutations and to the relatives of the 6 patients with VUS (3 in LDLR, 2 in APOB, and 1 in PCSK9; see Online Table 4 for details) that, based on the ACMG recommendations, could have been reclassified (23).
Familial screening was not possible or was rejected in 5 families (2 with pathogenic or likely pathogenic variants and 3 with VUS). Clinical and genetic study of 21 first-degree relatives from 10 families (7 with pathogenic or likely pathogenic mutations and 3 with VUS) was finally performed (Online Table 5 ). Familial evaluation did not allow reclassification of any VUS as pathogenic or likely pathogenic according to ACMG criteria (23) . Therefore, the final prevalence of genetically confirmed FH among ACS patients age 65 years with LDL-C 160 mg/dl was 8.7% (95% CI: 4.3% to 16.4%; n = 9) (Figure 2) .
Clinical, analytical, and treatment characteristics of ACS patients with and without FH mutations were compared ( Table 3) . When comparing FH diagnosis by genetic testing against FH clinical criteria, 4 patients (44%) with genetically confirmed FH were not diagnosed by DLC criteria and 3 (33%) failed to be confirmed using SB criteria (Table 4) .
Conversely, 82.1% (95% CI: 62.4% to 93.2%; n = 23) of patients diagnosed by the DLC algorithm and 78.6% (95% CI: 58.5% to 90.9%; n = 22) diagnosed by SB criteria did not show any FH mutation. Furthermore, 29.03% (95% CI: 18.5% to 42.13%; n = 18) of the individuals without FH genetic variants had a genetic score consistent with polygenic hypercholesterolemia. Of note, 3 patients who fulfilled DLC FH clinical criteria and who did not show genetic variants in FH-causing genes exhibited a genetic score suggestive of polygenic hypercholesterolemia. The familial study led to the diagnosis of 6 relatives with FH mutations, of whom 4 presented with elevated LDL-C levels or were already on statins (Online Table 5 ).
Finally, the retrospective nature of our study allowed us to analyze 1-year LDL-C levels in patients with ACS and with genetically confirmed FH identified in our study. Only 1 of the 9 patients had LDL-C levels <70 mg/dl, as recommended in guidelines. Two patients had levels between 70 and 100 mg/dl, and 6 patients had LDL-C levels >100 mg/dl, even though most of them were taking high doses of lipid-lowering drugs (Online Table 6 ).
DISCUSSION
This study described, for the first time, a complete genetic analysis of genes associated with FH in patients with ACS age ≤65 years and with LDL-C levels 160 mg/dl. Our study showed that the prevalence of genetically confirmed FH in these patients is approximately 9%. This is much lower than the estimated FH prevalence as determined by widely accepted clinical FH criteria (27% in our cohort), but at the same time much higher than what has been previously reported in other FH genetic screening studies (Central Illustration). Moreover, our study demonstrated that FH clinical algorithms do not accurately identify FH subjects among patients with ACS, but FH genetic testing in this population is useful to facilitate early diagnosis of patients and their relatives at risk.
Early recognition of FH is essential as many patients with FH are unaware of their disease, which is a major cause of early CHD. Identifying FH allows specific counseling for diet and cardiovascular risk factors, and ensures high-dose statin prescription and appropriate referral of family members for FH screening.
Recent European guidelines for prevention of CHD in FH underlined the utility of identifying causal mutations to facilitate cascade screening (24) . Although cascade screening is the best means to identify FH patients, as they can be identified before an event occurs, it requires prior identification of the FH probands, which is not an easy task.
Recent screening studies where participant selection was based solely on a single elevated LDL-C level were disappointing and reported FH mutations in fewer than 2% of severely hypercholesterolemic subjects (10, 11) . This low yield of FH diagnosis called into question the utility of genetic screening programs in unselected patients with high LDL-C levels; plus, it raised the need to find other clinical scenarios where genetic screening would yield a higher uptake (10) . Two approaches, national screening of infants with very high total cholesterol or primary care screening programs during routine immunization visits, have turned out to be very good strategies, as demonstrated by 2 recent studies from Slovenia and the United Kingdom (25, 26) . Unfortunately, implementing national screening programs in children is complex and this methodology cannot be applied in many countries. By contrast, identifying FH individuals during hospitalization for ACS could be of great interest in the absence of national FH screening programs. ACS might be the first manifestation of FH and a hard event like ACS could have a great impact among relatives, facilitating familial screening. Despite its suspected importance, the prevalence of genetically confirmed FH in ACS has never been investigated using a complete genetic approach, and the only reported study described a very low detection rate (27) .
Wald et al. reported a prevalence of FH of 1.3% in young patients (≤50 years) with myocardial infarction at a London hospital (27) . Unlike our study, the genetic analysis performed by these authors included a panel of 48 known FH mutations and whole exon deletions or duplications of LDLR regardless of cholesterol levels, followed by Sanger sequencing of LDLR in individuals without mutations and a total cholesterol >271 mg/dl (27) . By contrast, we used next-generation sequencing (NGS) to study the promoter, coding, and exon-intron boundary regions of 5 FH-causing genes. These methodological differences, plus a less restrictive patient approach (we included individuals ≤65 years and LDL-C 160 mg/dl), could explain the differences found between the studies and should be considered when designing genetic screening programs.
The prevalence of clinical familial hypercholesterolemia in ACS patients has been recently studied in Europe using FH clinical scores (13, 14) . In the Swiss SPUM-ACS (Special Program University Medicine-Acute Coronary Syndromes) cohort that included 4,778 patients with ACS, 1.6% (95% CI: 1.3% to 2.0%) of patients fulfilled criteria of probable-definite FH according to DLC criteria (14) . The prevalence of clinical FH was 4.8% in 1,451 patients with ACS and premature CHD (<55 years for men and <60 years for women) (14) . In more than 7,000 European patients with CHD from the EUROASPIRE (European Action on Secondary and Primary Prevention through Intervention to Reduce Events) IV study, the prevalence of probable-definite FH was 8.3% overall but 15.4% in the 2,212 patients who were <60 years (13) . Our study reported FH prevalence of 27.2% (95% CI: 19.1% to 37%) according to the DLC and the SB criteria. We think that the higher prevalence found in our cohort was partly related to the LDL threshold used, which selected individuals with higher pre-test probability. Additionally, data about clinical signs of lipid accumulation in tissue, as well as information on family history of elevated LDL-C, were not available to the SPUM-ACS authors and they decided that missing information counted as zero in the DLC algorithm (14) . By contrast, in our study, we were able to perform physical examination in all participants (the presence of xanthomas is one of the items that gives more points in the clinical scores) and also obtain data from their personal and family history. These 2 critical factors (LDL-C threshold and clinical or familial information) might explain the higher FH prevalence as determined by clinical criteria found in our study.
Nevertheless, one of the main findings of our study was the demonstration that FH clinical scores were unable to correctly identify ACS patients with and without FH. As shown here, 30% to 40% of patients with confirmed FH mutations were not detected using FH clinical scores, while more than three-quarters of patients with ACS diagnosed with FH by clinical scores did not harbor any FH mutation. Our findings aligned with recent publications (2, 28) that have also shown that clinical FH criteria were unable to identify FH individuals compared with genetic testing. Nevertheless, our results must be taken in the context of the ACS setting, where available information about FH prevalence is currently restricted to FH clinical criteria (13, 14) .
Recently, several opinion leaders in FH concluded that 3 parts of the FH clinical diagnostic criteria are no longer as useful as they once were (29) . With the widespread use of statins over the last 30 years, average LDL-C levels across the general population are lower, physical examination findings such as xanthomas are found less frequently, and family history information is less useful (i.e., there is the potential for less CHD development in FH families) (29) .
Our results also showed that FH clinical criteria do not seem to be useful in individuals with premature ACS, and the high FH genetic uptake found in our study would strongly favor the adoption of FH genetic-testing strategies over FH clinical criteria in this clinical setting. Interestingly, in our study, 23% of individuals without FH variants had a high score for polygenic hypercholesterolemia, which is also a relevant finding. Furthermore, 3 patients with a genetic score suggestive of polygenic hypercholesterolemia fulfilled FH clinical criteria and, in the absence of genetic study, their relatives would have had to undergo FH clinical screening according to current guidelines.
The National Institute for Health and Care Excellence cost-effectiveness study found that cascade screening was more efficient when guided by genetic testing for a known FH mutation (30) . Because of the FH genetic screening performed in this study, clinical FH screening is no longer necessary in relatives of numerous patients who did not present FH mutations irrespective of the clinical criteria findings of the proband.
The present study also provided some data on the impact of identifying genetically confirmed FH among patients with ACS. At 1-year follow-up, only 1 FH proband presented with recommended LDL-C levels <70 mg/dl even though most were receiving high doses of statin and, in some cases, ezetimibe, too. Recent data showed that FH patients identified by clinical criteria have a >2-fold adjusted risk of coronary event recurrence within the first year after discharge than patients without FH (12) ; other investigators have shown that a vast majority of FH patients do not reach LDL-C target levels for secondary prevention (12, 14, 31) . These results emphasized the need for better monitoring and utilization of available medication in patients with FH. Prompt recognition of FH status is extremely important to identify individuals with ACS and higher risk and who should be treated aggressively soon after the ACS event.
Finally, our study showed the benefits of FH genetic screening at the family level, as the maximum usefulness of FH genetic screening is not to identify subjects with FH who have already suffered an event, but rather to identify other FH subjects at risk of future events that can be avoided. In our study, FH genetic screening allowed diagnosis of FH in 6 firstdegree relatives who otherwise would have remained unidentified by clinical criteria in most cases. As an example of early FH diagnosis prompted by genetic screening in subjects with ACS, a 6-year-old girl with FH and an LDL-C of 202 mg/dl was identified in our study (see family 9 in the Online Appendix). Given the importance of early diagnosis of FH before an event occurs, we believe that genetic studies constitute a fundamental tool to improve prognosis of FH patients.
STUDY LIMITATIONS.
Most of the patients were Caucasian males, which might limit the external applicability of the results. LDL-C level was measured in the first 48 h after ACS admission, and some evidence suggests that LDL-C levels are decreased during this time.
Moreover, untreated LDL-C levels were estimated for those patients who were on statins or ezetimibe prior to admission. This approach might inaccurately estimate LDL-C given the heterogeneity in drug selection, dosing, and individual response and variability across baseline LDL-C levels or mutation status. Furthermore, NGS testing does not detect inversions and translocations. While these genetic abnormalities probably are not major causes of FH, we cannot address its effect in our cohort. Although cost of FH NGS genetic testing is now small (~300 to 350 Euros), and cascade FH screening is more efficient when guided by genetic testing, the cost-effective consequences of adopting a large-scale FH genetic screening program in patients with ACS following the criteria used in our study are unknown. Finally, the unicentric and retrospective nature of our work should be taken into consideration and our results must be replicated, ideally in a large prospective study.
CONCLUSIONS
Prevalence of genetically confirmed FH in ACS patients age ≤65 years and with an LDL-C 160 mg/dl is high (~9%). FH clinical algorithms do not accurately identify FH patients in this setting, with a substantial number of patients with genetically confirmed FH unidentified by clinical criteria, while there are also numerous individuals diagnosed with FH by clinical criteria without FH mutations and with a genetic score consistent with polygenic hypercholesterolemia. Our data support the view that clinical criteria should not be used to identify FH in this setting. Instead, we believe that FH genetic testing should be advocated in young patients with ACS and high LDL-C to allow prompt identification of FH patients and relatives at risk. (11) and with a primary care genetic screening program in children 1 to 2 years old during routine immunization visits (26) .
FIGURE 1 Patient Selection
This flow chart shows the successive steps taken during the study. *Estimated untreated LDL-C for those patients on statins or ezetimibe. ACS = acute coronary syndrome; LDL-C low-density lipoprotein cholesterol.
FIGURE 2 Genetic Testing Results
This diagram explained the results of the genetic study performed in patients with ACS. FH = familial hypercholesterolemia; VUS = variants of unknown significance; other abbreviations as in Figure 1 .
TABLE 1 Baseline Characteristics
Values are mean ± SD or n (%). On statins at admission, n (%) 39 (37.9%)
Other lipid-lowering agent, n (%) 8 (7.8%) 
